News & Trends - Pharmaceuticals
BMS/Celgene merger heads to a close after clearance from competition regulators
Bristol-Myers Squibb announced the approval from the U.S. Federal Trade Commission (FTC) to close the pending $74bn merger of Bristol-Myers Squibb and Celgene.
The merger could create the fourth largest pharma firm by revenue, behind Pfizer, Novartis, and Roche.
Celgene entered into an agreement with Amgen under which Amgen would acquire the global rights to psoriasis drug OTEZLA (apremilast). Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for Bristol-Myers Squibb’s pending merger with Celgene.
Bristol-Myers Squibb has now satisfied all regulatory requirements under the merger agreement to complete the acquisition of Celgene and expects to close the transaction on November 20, 2019. Bristol-Myers Squibb also expects the OTEZLA divestiture to be completed promptly following the closing of the merger.
“Today’s news is an exciting milestone in our company’s history as we look forward to officially combining with Celgene to create a leading biopharma company,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together we will be well positioned to discover, develop and deliver innovative medicines, and to transform the lives of more patients through science.”
Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
You may also like 91% of clinicians use reprints to improve patient care
Digital & Innovation
Targeted funding of digital health technologies key to unlocking $5 billion in savings: New report
Digital & Innovation: Integrating digital technology into healthcare more effectively could alleviate pressures on our healthcare system and lead to […]
MoreNews & Trends - MedTech & Diagnostics
Surgeons welcome ‘significant win’ for patients, amidst clash with health insurers
MedTech & Diagnostics News: The Royal Australasian College of Surgeons (RACS) is heralding a significant triumph for Australian patients following […]
MoreNews & Trends - Pharmaceuticals
Healthcare affordability and accessibility top priority for consumers ahead of Federal Budget
Pharma News: With the Federal Budget set to be delivered in just one week, the Consumers Health Forum of Australia […]
MoreHuman Resources
Novartis named finalist in LGBTQ+ Inclusion Awards
Human Resources: Novartis Pharmaceuticals Australia and New Zealand has been honoured as a finalist in the 2024 Australian LGBTQ+ Inclusion […]
More